Perimenopause Depression: Why Midlife Mental Health Feels Different

By Diane Dalais, Clinical Naturopath | In Thyme Naturopathy

When You Don’t Feel Like Yourself Anymore

For many women in their late 30s and 40s, something begins to shift in ways that are hard to explain. You may feel unlike yourself, more anxious, emotionally reactive, flat, or easily overwhelmed. Some women describe it as losing their spark. Others say they feel constantly on edge or less able to cope with things that never used to bother them.

When women seek help for these symptoms, they are often dismissed or diagnosed with depression or anxiety in isolation. The hormonal context is frequently overlooked. For many women, this represents a major gap in care, because the most important driver of their symptoms may not be psychological at all.

Perimenopause is not simply the reproductive system winding down. It is a neurological and hormonal transition that directly affects the brain. Fluctuating ovarian hormones influence mood, stress resilience, cognition, and sleep. Understanding this changes how we approach midlife mental health, and it can change outcomes for women significantly.

How Common Is Perimenopause-Related Depression?

The menopause transition is a recognised window of increased vulnerability for mood disorders.

Large long-term studies show that perimenopause roughly doubles the risk of clinically significant depressive symptoms compared to premenopausal years. A 2024 meta-analysis involving over 9000 women confirmed that perimenopausal women face an elevated risk of depression.

Australian data also highlights the seriousness of this issue. Suicide rates peak for women in midlife, and the 2024 Australian Senate inquiry into perimenopause and menopause emphasised how under-recognised and under-treated these symptoms remain.

This is not a minor quality-of-life issue. It is a significant and treatable public health concern and recognising perimenopause as part of the conversation is the first step.

What Happens in the Brain During Perimenopause?

Oestrogen is not just a reproductive hormone. It acts throughout the brain as a powerful neuromodulator. Oestrogen receptors are widely distributed across key brain regions involved in mood, cognition, and stress regulation, where they help modulate:

• Serotonin - mood stability and emotional resilience

• Dopamine - motivation, focus, and energy

• GABA - the brain’s primary calming neurotransmitter

• The stress response system (Hypothalamic-Pituitary-Adrenal axis [HPA axis]) - how strongly we react to stress

• Neuroplasticity (via Brain-derived neurotrophic factor [BDNF]) - the brain’s ability to adapt and learn

During perimenopause, oestrogen does not decline in a steady, linear manner. Instead, it fluctuates unpredictably, with significant hormonal swings. These fluctuations directly influence the brain’s internal neurochemical environment.

For many women, this may present as:

• Increased anxiety or irritability

• Reduced stress tolerance

• Brain fog and word-finding difficulty

• Sleep disruption (especially early waking at 3–5am)

• Tearfulness or low mood

Progesterone’s role is equally important. In the brain, progesterone is converted into allopregnanolone, a potent neurosteroid that enhances GABAergic activity and exerts a calming effect on the nervous system. As progesterone declines during perimenopause, this natural stress-buffering mechanism weakens. Life circumstances may remain unchanged, yet the nervous system’s capacity to absorb them is not.

In addition, monoamine oxidase A (MAO-A) is an enzyme responsible for breaking down key mood-regulating neurotransmitters, including serotonin, dopamine, and norepinephrine. Under stable hormonal conditions, oestrogen helps regulate and maintain balanced MAO-A activity. However, as oestrogen fluctuates and gradually declines in perimenopause, MAO-A activity is thought to increase.

Research has demonstrated that MAO-A binding is significantly higher in perimenopausal women compared to women of reproductive age, indicating a faster breakdown of mood-supportive neurotransmitters. This accelerated neurotransmitter turnover may contribute to feelings of anxiety, low mood, emotional sensitivity, reduced resilience, and motivational changes, even in women with no prior mental health history.

Elevated MAO-A activity has also been associated with increased oxidative stress in the brain, which may further contribute to cognitive symptoms frequently reported during perimenopause, including brain fog, reduced concentration, and memory lapses.

This neurochemical shift helps explain why symptoms can feel sudden, unfamiliar, and disproportionate to external life stressors. Anxiety, emotional sensitivity, reduced resilience, and motivational flatness are not simply psychological weaknesses, they are reflections of a changing hormonal and neurochemical environment.

Importantly, if neurotransmitters are being broken down more rapidly, approaches that focus solely on neurotransmitter reuptake (such as antidepressant medications) may not fully address the underlying drivers for some women. Recognising and supporting the hormonal context becomes a critical component of more targeted and effective care during perimenopause.

When Hormones Are Overlooked: Why Many Women Feel Misunderstood

Because menstrual cycles often continue during perimenopause, hormonal drivers of mood and anxiety can be easy to miss, especially for practitioners who are not specifically trained in this transition.

Many women spend years being treated for anxiety or depression with limited improvement because the hormonal component has never been addressed. Others are told their symptoms are simply stress or life-stage pressures.

Blood tests can sometimes add to the confusion. Confirmation that perimenopause has begun is determined primarily through symptom patterns, age, and menstrual history - not routine hormone panels. Hormone levels fluctuate significantly during this phase, meaning a single blood test may appear “normal” despite significant symptoms.

Recognising the hormonal context does not replace psychological or psychiatric care. It strengthens it, allowing treatment to become more targeted, individualised, and effective.

How to Recognise Perimenopause-Related Low Mood or Depression

Distinguishing perimenopausal mood changes from primary anxiety or depressive disorders can be complex and should always involve qualified healthcare professionals. These conditions can overlap. However, perimenopause-related mood changes often follow recognisable patterns:

• Strong physical sensations such as heart palpitations, hot flushes, or accompanying anxiety

• A cyclical or episodic pattern, with waves of irritability or low mood around ovulation or menstruation

• A “not myself” feeling, rather than persistent worthlessness or guilt

• First-time anxiety or depression in midlife without a significant prior history

• Brain fog and word-finding difficulty that fluctuate with hormonal shifts

• Early-morning waking between 3–5am

• Preserved outward functioning despite significant internal distress

• Partial or inconsistent response to treatment when hormones are not addressed

  
  

In clinical settings, validated tools such as the Menopause-Specific Depression (MENO-D) scale can be helpful alongside a thorough medical, hormonal, and psychosocial history. These patterns are not a substitute for diagnosis, but they are important clues that fluctuating hormones deserve attention.

Why Early Recognition Matters - And What This Season Can Bring to the Surface

Perimenopausal mood symptoms can feel more intense than at other life stages. Part of this is neurological. Part of it is the emotional weight many women carry into midlife.

This is often a period of extraordinary demand: raising children or teenagers, supporting ageing parents, navigating careers and relationships, and reassessing long-held expectations. When the brain’s hormonal buffer shifts, previously manageable stressors can feel overwhelming.

For some women, this transition also brings unresolved grief, old trauma, or long-suppressed emotions to the surface. This is not failure. It is often a signal from the nervous system that something needs care and integration.

With the right support, perimenopause can become a catalyst for meaningful change and a chance to reassess boundaries, priorities, and wellbeing.

Early recognition matters because prolonged untreated mood disturbance carries real consequences. Women who receive hormone-informed care earlier tend to experience better outcomes across mental, relational, and occupational health.

A More Complete Approach to Perimenopause Mental Health

Effective support addresses biology and life context together, rather than treating symptoms in isolation.

Moving Through Perimenopause With the Right Support

The most important message is this: midlife mood changes are not a personal failure. They are not weakness, and they are not permanent.

They are the predictable result of a profound brain and hormonal transition, one that is real, biological, and treatable when the full picture is understood.

With the right support, women can move through perimenopause feeling informed, steady, and increasingly clear rather than confused or dismissed.

For many women, this transition becomes more than symptom management. It becomes a turning point, an invitation to reconnect with themselves.

If you recognise yourself in what you’ve read, the next step is not self-diagnosis. It’s working with a practitioner who understands the intersection of hormones and mental health.

Download my free Perimenopause Guide for clear, evidence-informed education on what this transition may mean for your body and mind, along with practical, foundational diet and lifestyle strategies to help you navigate it with greater clarity and confidence here.

If you're looking for more personalised support, you can also explore the Perimenopause Package, more information can be found here

References

1.

Australian Institute of Health and Welfare [AIHW]. Suicide and Self-harm Monitoring [Internet]. Aihw.gov.au. 2025. Available from: https://www.aihw.gov.au/suicide-self-harm-monitoring/overview/summary

2.

Behrman S, Crockett C. Severe mental illness and the perimenopause. BJPsych Bulletin [Internet]. 2023 Nov 13;48(6):1–7. Available from: https://www.cambridge.org/core/journals/bjpsych-bulletin/article/severe-mental-illness-and-the-perimenopause/8D072AACBCD3C7888C173B36635C08C3

3.

Kulkarni J, Gurvich C, Mu E, Molloy G, Lovell S, Mansberg G, et al. Menopause depression: Under recognised and poorly treated. Australian and New Zealand journal of psychiatry. 2024 May 18;58(8).

4.

Maki PM, Kornstein SG, Joffe H, Bromberger JT, Freeman EW, Athappilly G, et al. Guidelines for the evaluation and treatment of perimenopausal depression. Menopause [Internet]. 2018 Oct;25(10):1069–85. Available from: https://www.menopause.org/docs/default-source/default-document-library/meno-d-18-00170-final.pdf

5.

Badawy Y, Spector A, Lee Z, Desai R. The risk of depression in the menopausal stages: A systematic review and meta-analysis. Journal of affective disorders. 2024 Apr 1;357:126–33.

6.

Study of Women’s Health Across the Nation [SWAN]. Depression and Menopause | SWAN Women’s Study [Internet]. SWAN - Study of Women’s Health Across the Nation. 2024 [cited 2026 Jan 12]. Available from: https://www.swanstudy.org/womens-health-info/depression-menopause/

7.

Crockett C, Lichtveld G, Macdonald R, Newson L, Rampling KJ. Menopause and Mental Health. Advances in Therapy. 2025 Nov 21;43(1):98–108.

8.

Kulkarni J. Perimenopausal depression - an under-recognised entity. Australian Prescriber. 2018 Dec 3;41(6):183–5.

9.

Commonwealth of Australia. Issues related to menopause and perimenopause [Internet]. Aph.gov.au. Commonwealth of Australia; 2024. Available from: https://www.aph.gov.au/Parliamentary_Business/Committees/Senate/Community_Affairs/Menopause/Report